Trump Administration Reclassifies Medical Marijuana, Unlocking Major Tax Breaks for Cannabis Businesses

WASHINGTON — The Trump administration on Thursday reclassified state-licensed medical marijuana as a less dangerous substance, a landmark policy shift that recognizes its medicinal value and provides a significant financial windfall to cannabis businesses by allowing them to take federal tax deductions for the first time. The order, signed on April 23, 2026, by acting Attorney General Todd Blanche, moves medical marijuana from Schedule I of the Controlled Substances Act to the less-restrictive Schedule III. The move, which follows a December executive order from President Donald Trump, represents one of the most substantial changes in federal cannabis policy since the Marihuana Tax Act of 1937 effectively began its prohibition. Under federal law, Schedule I substances, such as heroin and LSD, are defined as having a high potential for abuse and no accepted medical use. The reclassification places medical cannabis in a category alongside substances like ketamine and some anabolic steroids, which are recognized as having a moderate to low potential for physical and psychological dependence and have accepted medical applications. This action directly addresses a long-standing conflict between federal law and the policies of most states. According to reports, 40 states have established medical marijuana systems, and two dozen have authorized adult recreational use. The federal government’s previous stance created significant operational and financial hurdles for state-licensed businesses operating in a multi-billion dollar industry. The most immediate and concrete impact of the reclassification is on the tax liabilities of medical cannabis companies. As a Schedule I substance, marijuana businesses were barred from deducting ordinary business expenses, such as payroll and rent, on their federal tax returns. This forced them to pay an effective tax rate that could reach 60% of their gross revenue, a crippling burden for many operators. The move to Schedule III lifts this restriction, allowing these companies to be taxed like any other legal business, which is expected to dramatically improve their profitability and ability to invest in growth. While the order is a major victory for the medical cannabis industry, it does not legalize marijuana at the federal level. Possessing, selling, or cultivating marijuana remains a federal crime. The reclassification signed by Blanche applies only to state-licensed medical marijuana and any marijuana-derived medicines approved by the Food and Drug Administration. Marijuana sold for recreational purposes, even in states where it is legal, remains a Schedule I controlled substance under federal law. However, the order is also expected to accelerate scientific and medical research into cannabis. Researchers have long complained that the Schedule I designation created prohibitive bureaucratic hurdles and limited access to the substance for study. The less-burdensome requirements for Schedule III substances are expected to facilitate more robust research on the safety and efficacy of marijuana for various medical conditions. In his statement, Blanche noted the change will provide “patients with better care and doctors with more reliable information.” Criminal penalties for offenses involving Schedule III drugs can also be less severe than those for Schedule I substances. That said, a long-standing congressional provision has prevented the Department of Justice from using federal funds to prosecute cannabis activity that is legal under state medical marijuana laws. This reclassification does not alter that protection, which has provided a crucial shield for the industry. For cannabis businesses, this regulatory shift is a landmark financial event, but navigating the new tax landscape will require careful planning. While the ability to deduct standard business expenses is a game-changer, companies cannot simply flip a switch. They must immediately re-evaluate their entire accounting framework, determine the applicability of the new rules to their specific operations, and prepare for new guidance that the IRS will undoubtedly issue. In our experience, major regulatory changes often create periods of uncertainty and compliance risk. Business owners who proactively adjust their financial strategies will be best positioned to capitalize on this opportunity without running afoul of new requirements. This is precisely the kind of complex situation where our tax preparation and compliance services become essential for ensuring a smooth transition. To understand how this reclassification affects your specific operations, business owners should contact C&S Finance Group LLC at csfinancegroup.com. Looking ahead, the policy shift on medical marijuana may be a precursor to broader changes. The Department of Justice has scheduled a hearing for June 29 to consider a general reclassification of all marijuana, including recreational, to Schedule III. This upcoming hearing will be closely watched by stakeholders as a potential next step in the evolution of federal cannabis policy.